Tag: VEITH 2023
Changing course: The natural history of tibial claudication comes under scrutiny...
In the end, reflected Michael S. Conte, MD, “it’s not the evidence.” The leading vascular surgeon and peripheral arterial disease (PAD) expert made the...
Vascular Specialist–December 2023
In this issue:
Changing course: The natural history of tibial claudication comes under scrutiny as interventions for "relatively benign" disease trend upward
Our guest editorial...
TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of...
Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics' TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18...
Twelve-month first-in-human data from Xeltis’ aXess haemodialysis vascular conduit trial presented...
Xeltis has announced "highly encouraging" 12-month results from its first-in-human (FIH) aXess vascular conduit trial. The data were presented by Frans Moll (University Medical...
Randomized trial set to elucidate value of image fusion technology for...
An ongoing UK National Institute for Health and Care Research (NIHR)-funded randomized controlled trial seeks to illuminate the value of an image fusion guidance...
Two-year SWING data ‘continue to show promise’ for sirolimus DCB in...
Two-year data from the SWING trial, a first-in-human study of the safety and performance of the Sundance sirolimus drug-coated balloon (DCB; Surmodics), have been...
Specialty representation at all levels of a healthcare organization is ‘increasingly...
A 14-year effort to achieve departmental status for vascular surgery at a large healthcare system in Southern California resulted in significant gains for the...